Morningstar Views: The 10 Biggest IPOs of 2020

Most companies that went public this year faced tremendous uncertainty. But those that braved the tumultuous conditions were rewarded with a perfect storm of demand. According to PitchBook, as of Dec. 14, there were 1,291 initial public offerings completed worldwide, raising around USD 331.47 billion. Though the number of deals are in line with previous years, the amount of capital raised was higher.

Notably, a group of giants–10 of them alone–now make up almost half a trillion in market cap.

Investing Is a Marathon, Not a Sprint

These numbers might prompt individual investors to jump into IPO investing. But that might not be a good idea. 

Morningstar Canada’s director of investment research Ian Tam cautions on the price action in the lead up to IPO stocks hitting the secondary market.

“For the individual retail investor, getting a ‘piece’ of an IPO at the stated initial offering price will likely prove to be a challenge since the majority of the shares are typically scooped up in large blocks in advance by institutional investors. The close price after the first day of trading may provide a better indication of the price at which shares are available,” he said, adding that the path to financial freedom is a marathon, not a sprint. 

What should individual investors do?

“If you plan to hold the stock over a longer time frame, consider comparing the current stock price against the fair value estimate of the stock. Having a long-term fundamental view of the company will not only provide insights to whether you’re overpaying but may also let you sleep at night.”
 

2020’s Biggest IPOs


Here are the biggest single IPO deals by size and subsequent gains in market cap this year.

Market cap and returns to date are as of Dec. 14. Source: Pitchbook and Morningstar.


Warner Music Group (WMG)
IPO: June 3, 2020
Deal Size: USD 1.93 billion
Current Market Cap: USD 16.7341 billion
Approx. returns since IPO: + 31% – USD 32.86 (USD 25 starting price) 

The first big deal waited for markets to begin to calm, with Warner Music–or rather, senior shareholders of the record label company–deciding to sell some stock. None of the proceeds went to the company itself; however, public shareholders eventually benefited after the stock nearly bounced off its IPO price at the end of October.


Li Auto (LI)
IPO: July 30, 2020
Deal Size: USD 1.092.50 billion
Current Market Cap: USD 29.2804 billion
Approx. returns since IPO: +260% – USD 30.83 (USD 11.50 starting price)

Li Auto’s high-end and hybrid electric vehicle offerings are riding a Chinese electric vehicle boom. “China’s share of total global EV sales is also growing at an astonishing rate”, says Elliot Johnson, who leads the Evolve Automobile Innovation Index Fund (CARS) at Evolve ETFs. “Factors driving this growth include the increasing size of China’s domestic market for consumer goods, economies of scale driving down prices, technological advances improving battery range, and the increased roll-out of charging stations,” he says.


Rocket Companies (RKT)
IPO: Aug. 6, 2020
Deal Size: USD 1.80 billion
Current Market Cap: USD 43.2313 billion
Approx. returns since IPO: +21% – USD 21.80 (USD 18 starting price)


This Detroit-based mortgage company has combined the power of podcast and omnichannel advertising with government-sponsored and insured products in the United States. The company’s flagship product is Rocket Mortgage, and it has since launched offerings in industries like auto sales and personal lending. Investors have made modest gains on this stock as it seeks to reclaim a peak in mid-November.


X Peng (XPEV)
IPO: Aug. 27, 2020
Deal Size: USD 1.50 billion
Current Market Cap: USD 32.9133 billion
Approx. returns since IPO: +209% – USD 46.47 (USD 15 starting price)


X Peng competes against Li Auto and targets the same luxury segment as NIO–the original Chinese EV stock. “Strong competition between NIO, X Peng, LI Auto, and Tesla proves an important point: The high demand in China means there is room for all of them,” says Johnson. “All four will struggle to meet demand in 2021 and 2022, as their biggest challenge will be how to scale up production while maintaining margins, along with the possibility of needing to raise more capital. Bottom line: This is not a zero-sum game in the Chinese market like it is in developed economies.”


Snowflake (SNOW)
IPO: Sept. 16, 2020
Deal Size: USD 3.36 billion
Current Market Cap: USD 93.2786 billion
Approx. returns since IPO: +273% – USD 328.45  (USD 120 starting price)


Some call Snowflake a “data warehouse-as-a-service,” or a company that takes on the weight of maintaining data so that it’s available when you need it. Early investors profited by predicting the growing demand for efficient storage as the stock rose around 216% since IPO.


Unity Software (U)
IPO: Sept. 18, 2020
Deal Size: USD 1.30 billion
Current Market Cap: USD 45.2874 billion
Approx. returns since IPO: +192% – USD 144.36 (USD 75 starting price)


Unity is a standard piece of software for 2D and 3D content designers across a wide variety of platforms, from smartphones to consoles and VR headsets. Since its launch, the stock’s steadily climbed to more than double its original trading price. 


GoodRx Holdings (GDRX)
IPO: Sept. 23, 2020
Deal Size: USD 1.14 billion
Current Market Cap: USD 17.2877 billion
Approx. returns since IPO: +33% – USD 44.35  (USD 33 starting price)


It’s understandable to believe that a healthcare app stock would soar in a pandemic–and it did–but now it’s nearing where it started.


Palantir (PLTR)
IPO: Sept. 30, 2020
Deal Size: USD 2.5714 billion
Current Market Cap: USD 50.6648 billion
Approx. returns since IPO: +270% – USD 26.97 (USD 10 starting price)


Palantir emerged on the markets as a mysterious baron of Big Data. It had the big U.S. government contracts and combined that with data analytics and artificial intelligence. The stock has soared to around double our fair value estimate, but we remain optimistic, especially in the B2B space. “For the commercial segment, we expect strong growth as more companies and industries strive to understand actionable insights from their data stores and new data generated,” says equity analyst Mark Cash.
                       
                                
DoorDash (DASH)
IPO: Dec. 9, 2020
Deal Size: USD 3.37 billion
Current Market Cap: USD 49.2371 billion
Approx. returns since IPO: -16% – USD 156.13 (USD 185 starting price)


DoorDash has become a food-tech ally, as households sought to add some variety and convenience to restricted dining options at home. With the IPO launching just as the vaccine rolls out, we’ll soon see how many now prefer dining-in over dining-out.


Airbnb (ABNB)
IPO: Dec. 10, 2020
Deal Size: USD 3.51 billion
Current Market Cap: USD 101.114 billion
Approx. returns since IPO: -14% – USD 127.92 (USD 146 starting price)


Frustration with booked-up hotels near a conference led these founders to take an air mattress and a website called “Air Bed and Breakfast” and grow to an app that’s logged billions of booked nights. It should continue to grow, but for now, we think it’s worth around USD 60.
 

It’s a Bull Market, Of Course

You may have noticed that these IPOs were mostly success after success. While the pandemic is trying times, these IPOs operated in the separate world of Wall Street and Bay Street, on a separate timeline, and benefited from the energy poured into an economic recovery. Keep an eye on underlying conditions, and remember: It’s a marathon, not a sprint.


Morningstar Disclaimers:

Since its original publication, this piece may have been edited to reflect the regulatory requirements of regions outside of the country it was originally published in.

The opinions, information, data, and analyses presented herein do not constitute investment advice; are provided as of the date written; and are subject to change without notice. Every effort has been made to ensure the accuracy of the information provided, but Morningstar makes no warranty, express or implied regarding such information. The information presented herein will be deemed to be superseded by any subsequent versions of this document. Except as otherwise required by law, Morningstar, Inc or its subsidiaries shall not be responsible for any trading decisions, damages or losses resulting from, or related to, the information, data, analyses or opinions or their use. Past performance is not a guide to future returns. The value of investments may go down as well as up and an investor may not get back the amount invested. Reference to any specific security is not a recommendation to buy or sell that security. It is important to note that investments in securities involve risk, including as a result of market and general economic conditions, and will not always be profitable. Indexes are unmanaged and not available for direct investment.

This commentary may contain certain forward-looking statements. We use words such as “expects”, “anticipates”, “believes”, “estimates”, “forecasts”, and similar expressions to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially and/or substantially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason.

The Report and its contents are not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Morningstar or its subsidiaries or affiliates to any registration or licensing requirements in such jurisdiction.


MeDirect Disclaimers:

This information has been accurately reproduced, as received from Morningstar, Inc. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or
solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment and may be deducted from the invested amount therefore lowering the size of your investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your
investment return therefrom. Any decision to invest should always be based upon the details
contained in the Prospectus and Key Investor Information Document (KIID), which may be obtained from MeDirect Bank (Malta)
plc.

Blue Whale Update: How Blue Whale views and manages risk

Stephen Yiu - Blue Whale Fund Manager Stephen Yiu is the Chief Investment Officer at Blue Whale Capital and Lead Manager of the Blue Whale Growth Fund.
Stephen co-founded Blue Whale Capital with Peter Hargreaves, co-founder of Hargreaves Lansdown, in 2016. The Blue Whale Growth Fund was launched in September 2017 and is a long-only global equity fund focusing on developed markets.
Stephen adopts a high conviction, active approach based on bottom-up, fundamental research.

When Odysseus, a hero of the Trojan War, sailed home through the Strait of Messina, he was warned to do so with great caution, for on both sides of the strait lay danger – a six-headed man-eating monster on one and a giant whirlpool on the other. Odysseus navigated the passage cautiously through the middle and delivered the ship and crew closer to home and safety.

We find this to be an apt metaphor for managing a portfolio of 25-35 holdings in the stormy seas of global equity markets. There are many risks and dangers that lurk around a surging market rally. Therefore, to deliver consistent significant outperformance successfully, we must navigate the choppy waters with hard work and discipline.

What is risk?

Volatility is not risk

Many professional investors take volatility as an indicator of risk; our view is quite different.

Firstly, share price volatility is hardly ever an indicator of company quality. As owners of Adobe and PayPal, if we had managed risk by simply looking at volatility then we would have established only small positions in these high quality businesses or sold out of them long ago – to the detriment of our investors.

Secondly, volatility can be a good thing, providing opportunities to buy high quality companies during short-term depressions in price.

Lastly, in the pursuit of limiting volatility via diversification, one often ends up with returns no better than a passive index fund.

How Blue Whale views risk

Quite simply, we define risk as a permanent loss of capital.

A permanent loss of capital can occur at the company level (bankruptcies, fraud, mismanagement etc.), industry level (technological/creative disruption) and at the market and macro levels through critical changes in economic output and political interference.

By viewing risk as the danger to outperformance from an irreversible loss of capital, we can better focus on how to manage and mitigate it.

How Blue Whale manages risk

We start by accepting, like in the Serenity Prayer, that there are things we cannot change.

Throughout the history of markets, there have always been testing periods when share prices went sideways or down. We accept that we cannot predict or control these years of lean market performance. If an investor sold their holdings during these times, they could well recognise a permanent loss of capital.

However, as long term investors, we believe that staying invested is the best way to ride out any storm. Although we cannot guarantee positive performance forever, we have developed a risk management framework to help us through turbulent times.

The North Star of our framework is our understanding of risks and their likelihoods. For risks where outcomes are clearer, we manage our exposure through our in-house fundamental research and our strict valuation discipline:

By investing in only high-quality businesses, many company-level risks are simply eliminated through our in-house research process: we do not invest in companies and industries that are getting disrupted (conversely we like the companies doing the “disrupting”) or experiencing weakening competitive position; we do not invest in companies with high debt or potential cash flow problems; nor do we invest in companies that are weak on corporate governance and where there is little or no alignment between management and shareholders. This means that high quality companies, even if they have highly volatile share prices, are actually less risky.

For macro-level risks, we are not in the business of second-guessing the Bank of England or the US Fed so we focus on what is within our control, namely: stress testing our companies’ balance sheets and cash flows through recessions and adverse scenarios; speaking with company representatives to ascertain the impact of geopolitical events. In short, we develop a thorough understanding of the impact of macro risks on our portfolio holdings and we act accordingly.

For market-level risks, we exercise a strict valuation discipline. We do so by assiduously monitoring industry and market developments with the aim of ensuring that market prices do not run significantly ahead of company fundamentals. When we see a company’s valuation getting frothy, we will reduce the holding and channel capital into other, less expensive, high quality businesses. If the market itself becomes frothy, we are not averse to increasing our cash holding.

For risks where there is more uncertainty, we can choose to either eliminate, accept or reduce our exposure. For example:

  • We decided to eliminate our COVID risk exposure through IHG because the return to revenue and cashflow growth in the business was highly uncertain.
  • On the other hand, in the case of Mastercard and Visa, we decided to accept the COVID risk coming from reduced cross-border travel spend as this would be partly mitigated by an acceleration in online and digital card payments.
  • We decided to reduce our exposure to market risk in the case of Amazon, which had rallied significantly on the back of strong eCommerce revenues during the pandemic. We exercised our strict valuation discipline and took the company out of our top 10 holdings in Q3 2020.

Our risk management framework, like our research process, is straightforward but not easy. It is, however, absolutely necessary if we are to continue charting a course to delivering consistent significant outperformance for our investors.

Dealing with Uncertainty through 2021 and beyond

The classical scholars out there will be quick to point out that Odysseus didn’t get past the dangers completely unscathed – he’d lost six of his crew to the six-headed monster perching on one side of the cliffs in the Strait of Messina. However, therein lies the lesson in risk management: the rest of his four-dozen men and the entire ship sailed through, achieving Odysseus’s primary objective.

Though young, many in our team have experienced multiple market cycles, and we therefore accept that not all our holdings will be perennial outperformers. We are aware of the risks and uncertainties out there. However, we prefer to be decisive in the face of uncertainty rather than be paralysed by it. We accept the risks, and we take action to manage, monitor and mitigate them with all the tools we have available to us. That’s what active investing is all about.

2020 has certainly been a year full of risks and dangers but we are glad to report on successfully delivering outperformance for our investors. In 2021 we will take the example of Odysseus with us – cautiously navigating the route ahead of us, remaining vigilant and with the aim of continuing to deliver consistent significant outperformance for our investors.

LF Blue Whale Growth Fund is manufactured by Blue Whale Capital LLP and represented in Malta by MeDirect Bank (Malta) plc.


Blue Whale Key Risks & Disclaimers:

The opinions, data, and analyses presented herein is issued for information only by Blue Whale Capital LLP (“Blue Whale”) which is a limited liability partnership incorporated in England and Wales under number OC414255. Blue Whale is authorised and regulated by the Financial Conduct Authority (“FCA”).

The contents presented herein are based upon sources of information believed to be reliable, however, save to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to its accuracy or completeness and, Blue Whale, its members, officers and employees do not accept any liability or responsibility in respect of the information or any views expressed herein. All data is sourced from Blue Whale unless otherwise stated.

The contents herein may include or may refer to documents that include forward-looking statements that are based upon our current opinions, expectations and projections. We undertake no obligation to update or revise any forward-looking statements. Actual results could differ materially from those anticipated in the forward-looking statements. The views we express on holdings do not constitute Investment Recommendations and must not be viewed as such.

There are significant risks associated with investment in the Fund referred to herein. Investment in the Fund is intended for investors who understand and can accept the risks associated with such an investment including potentially a substantial or complete loss of their investment.

Past performance is not a guide to future performance. The value of investments and any income derived from them can go down as well as up and the value of your investment may be volatile and be subject to sudden and substantial falls.

Investment in a Fund with exposure to emerging markets involves risk factors and special considerations which may not be typically associated with investing in more developed markets. Political or economic change and instability may be more likely to occur and have a greater effect on the economies and markets of emerging countries. Adverse government policies, taxation, restrictions on foreign investment and on currency convertibility and repatriation, currency fluctuations and other developments in the laws and regulations of emerging countries in which investment may be made, including expropriation, nationalisation or other confiscation could result in loss to the Fund.

Income from investments may fluctuate. Changes in rates of exchange may have an adverse effect on the value, price or income of investments. Fund charges may be applied in whole or part to capital, which may result in capital erosion. The Authorised Corporate Director may apply a dilution adjustment as detailed in the Prospectus. The Fund is not traded on an exchange or recognised market.

The foregoing list of risk factors is not complete, and reference should be made to the Fund’s Prospectus, KIID and application form.


MeDirect Disclaimers:

This information has been accurately reproduced, as received from Blue Whale Capital LLP. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment and may be deducted from the invested amount therefore lowering the size of your investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Investor Information Document (KIID), which may be obtained from MeDirect Bank (Malta) plc.

Liontrust Insights: 2020 – Words of this unprecedented year

By John Husselbee, Head of Multi Asset at Liontrust Asset Management

 

Annual reviews are always challenging to write, with many ending up as little more than a list of market and macro events and some mild crystal ball gazing to finish. With 2020, it is hard to know where to start given everything that has transpired and, if anyone needed reminding, the year has also exposed the futility of making economic predictions: in December 2019, no one was predicting a small strand of replicating protein would bringing the activities of the most successful species on the planet to a near standstill for large swathes of the next 12 months.

With this in mind, we have borrowed the approach of Oxford Languages, who have faced their own struggles when trying to review 2020. In the past, the language specialist has always come up with a word of the year (2016 gave us post-truth for example) but the events of the last 12 months, and the linguistic development required to capture them, has meant a whole list of words of 2020 rather than a single representative.

This framework gives a good indication of how such an unprecedented year has developed (definitely the word of the early Covid months, with every market review and article at pains to stress the exceptional situation). If we go back to pre-Covid however – or BC, which makes the list – the dominant words highlight factors that should continue to shape the future when the world can finally look past the current crisis.

We came into 2020 with markets fairly buoyant on the back of positive news of a potential trade deal between the US and China and some clarity on Brexit negotiations, two issues that had dominated headlines and sentiment for the previous few years. At this point, there were only rumblings of a viral outbreak in China and the risk this would spread to the West was far from most investors’ minds.

With climate emergency Oxford Languages’ term of 2019, this focus continued into 2020 with bushfires a key word in January as Australia’s season was the worst on record, coming to be known as the Black Summer. While media attention on climate change has understandably dropped off amid the pandemic, there are signs of this long-term focus returning to public consciousness and we will come back to the area later.

Politics and economics tend to be common areas of changing language, with squeezed middle, big society, and credit crunch all previous words of the year, and the main focus of 2020 has been the US presidential story, which culminated in a tumultuous victory for Joe Biden in November (again, more on that later). In February, controversy continued to swirl around President Trump and impeachment and acquittal were common words around the trial, just the third in history after Andrew Johnson and Bill Clinton.

While cases of that ‘virus’ had continued to escalate in China, numbers began picking up in the UK and other countries from March. This led to use of Coronavirus spiking before giving way to Covid-19 and now well-worn phrases such as lockdown, social distancing, remote working and furlough (the latter previously a military term) in April and beyond as the grim reality hit home. To give a quick history lesson, the word Coronavirus dates from the 1960s, but before 2020 it was largely the preserve of scientific and medical specialists. Covid-19 is a completely new word this year, first recorded on 11 February in a report by the World Health Organisation (WHO) as an abbreviation of coronavirus disease 2019.

These early stages also saw the description of the disease move from epidemic, meaning widespread in a community, to pandemic, where it has spread far more widely, across a whole country, multiple countries, or ultimately the world. Before this year, epidemic was the more commonly used, but on 11 March, WHO announced it was characterising Covid-19 as a pandemic, and its frequency has increased over 57,000% since last year. As countries around the world came to realise the serious nature of the disease, language around it also became more militaristic, with frontline medical staff battling the pandemic.

Some of the less pugilistic terms to emerge have included mask shaming (for those unwilling to wear the now uniform face coverings), covidiot (referring to someone who disobeys guidelines), and, a potentially key demographic when writing this outlook piece in the 2050s, coronials, the generation of babies conceived during lockdown.

Tracking the changing situation as the year progressed, we saw phrases such as shelter-in-place (in the US) and self-isolate give way to reopening and easing in summer, with people able to form support bubbles with other households where necessary. As a second wave subsequently descended and new lockdowns were introduced, terms such as firebreak, circuit breaker and tier increased in September and October, all signifying different levels of restrictions around the world. Before the more positive vaccine news of recent weeks, the UK’s mounting desperation to apply positive spin to the situation was signified by the use of moonshot as the name of a mass testing programme, with this word rocketing to the top of usage charts in September.

Another result of something so all-encompassing as Covid-19 has been a surge in amateur epidemiology, and the government’s own claim to be following the science is a phrase that has increased in frequency over 1,000%. Most of us are now perfectly happy discussing superspreaders and the R number, with terms such as flattening the curve part of everyday small talkas is ongoing concern at the lack of personal protective equipment.

Beyond Covid, black awareness rightfully gained greater prominence this year and Black Lives Matter rose in usage from June and remained high as protests against law enforcement over the killings of George Floyd, Breonna Taylor and others have continued. This febrile atmosphere was a key part of the US election, which proved among the most controversial in history and the losing candidate is still refusing to accept defeat at the time of writing. Much of the Trump camp’s attempt to interfere with the result focused on forcing recounts, with huge numbers of Americans – 80 million, twice the number from 2016 – voting by mail. Mail-in was therefore a heavily used phrase in the autumn, with a 3,000% rise compared to last year.

Moving towards the end of 2020, there are signs of people looking beyond this year and its challenges, with net zero in heavy use on the back of commitments to a green industrial revolution in the UK and the historic pledge by President Xi Jinping in September that China will be carbon neutral by 2060. Of course, Covid’s tentacles have also stretched into the world of climate change, with a new term, anthropause, coined in June to describe some of the more welcome ecological consequences of lockdown.

As we start to think about 2021, we would add our own word to the list in the shape of efficacy, with people around the world preoccupied with success rates of the various vaccines emerging to combat the virus. Use of the word vaccine has obviously increased hugely (by 400% compared to last year), as has anti-vaxxer, with controversy expected as governments attempt widespread rollouts.

With 2020 showing the lack of value in economic guesswork, what is worth saying as we head into another year? There is clearly considerable economic uncertainty despite vaccine news, with spiralling unemployment and huge debt burdens – and these are global rather than regional issues; for once, most of the world is genuinely in the same boat so we are likely see ongoing collaboration between central banks and governments to support recovery.

After a difficult year – and longer if we consider the shadow of trade wars – 2021 does at least promise the end of three market-influencing factors, which could mean more market clarity than has been the case for some time: the first is the transition from Donald Trump to Joe Biden, the second is a reduction in the impact of Covid-19, and the third is the Brexit fiasco.

We expect the current divided US government (with Republicans retaining the Senate and Democrats the House) to remain and this could mean stimulus to combat Covid is slower to come than needed. A broader return to more traditional politics and a calmer approach to international relations could be positive for the rest of the world, however, after a long period of trade volatility and increasingly protectionist policies. If nothing else, Covid-19 has reminded the world we are all one species and can achieve more together than divided.

Elsewhere, the hope is that the vaccines already announced, and others to come, bring an end to Covid uncertainty and recent market moves suggest investors have at least been able to recalibrate expectations for many companies now that some return to normality is in sight. Finally, after more than four years of wrangling, the Brexit situation is close to its endgame, for good or ill, and I echo the view of our UK equity manager at Liontrust Anthony Cross, who has said that once the politicians get out of the way, companies can come in and make the best of whatever situation emerges.

There remains uncertainty in all three of these areas but, if nothing else, they should bring more clarity in 2021. This may help restore the disconnect between stock market hope and economic reality, which, for us, has continued to underpin – and simultaneously undermine – surging stock markets throughout this year, particularly in the US where narrow tech leadership still prevails.

 


Liontrust Key risks and Disclaimers


Past performance is not a guide to future performance. Do remember that the value of an investment and the income generated from them can fall as well as rise and is not guaranteed, therefore, you may not get back the amount originally invested and potentially risk total loss of capital. The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term. Investment in the GF High Yield Bond Fund involves foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. The value of fixed income securities will fall if the issuer is unable to repay its debt or has its credit rating reduced. Generally, the higher the perceived credit risk of the issuer, the higher the rate of interest. Bond markets may be subject to reduced liquidity. The Fund may invest in emerging markets/soft currencies and in financial derivative instruments, both of which may have the effect of increasing volatility.

Issued by Liontrust Fund Partners LLP (2 Savoy Court, London WC2R 0EZ), authorised and regulated in the UK by the Financial Conduct Authority (FRN 518165) to undertake regulated investment business. This document should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. It contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, faxed, reproduced, divulged or distributed, in whole or in part, without the express written consent of Liontrust. Always research your own investments and (if you are not a professional or a financial adviser) consult suitability with a regulated financial adviser before investing. 


MeDirect Disclaimers

This information has been accurately reproduced, as received from Liontrust Fund Partners LLP. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment and may be deducted from the invested amount therefore lowering the size of your investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest should always be based upon the details contained in the Prospectus and Key Investor Information Document (KIID), which may be obtained from MeDirect Bank (Malta) plc.

 

Login

We strive to ensure a streamlined account opening process, via a structured and clear set of requirements and personalised assistance during the initial communication stages. If you are interested in opening a corporate account with MeDirect, please complete an Account Opening Information Questionnaire and send it to corporate@medirect.com.mt.

For a comprehensive list of documentation required to open a corporate account please contact us by email at corporate@medirect.com.mt or by phone on (+356) 2557 4444.